Dr. Reddy's Laboratories Share Price Drops Amid Semaglutide Batch Issues
Dr. Reddy's Laboratories shares fell approximately 9% following the company's disclosure of a ₹2.4 billion provision ($28.7 million) linked to out-of-spec semaglutide batches.
Dr. Reddy's Laboratories (NYSE: RDY) experienced a significant share price decline of approximately 9% in late July. The drop occurred after the pharmaceutical company announced a provision of ₹2.4 billion (approximately $28.7 million) related to batches of its semaglutide product that did not meet specifications.
Semaglutide is a key active ingredient used in widely prescribed diabetes medications. The issue with these specific batches could impact the company's supply chain and financial performance. The disclosure of this provision has raised concerns among investors regarding the scale of the problem and its potential financial ramifications.
In response to the share price drop and the provision announcement, the law firm Levi & Korsinsky has initiated an investigation into Dr. Reddy's Laboratories' securities. This investigation aims to determine if the company made any misleading statements or omitted material information to investors prior to the stock's decline.
The investigation will scrutinize the company's communications and disclosures leading up to the event. Shareholders who have suffered losses are being invited to inquire about potential legal recourse.